|
000
| 02705nam 2200409zi 4500 |
|---|
| 001 | 9.885893 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107171257 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 200417t20202020onca ob f000 0 eng d |
|---|
| 020 | |a9780660345697 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH82-49/2020E-PDF |
|---|
| 245 | 00|aBudget impact analysis guidelines : |bguidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. |
|---|
| 250 | |aSecond edition. |
|---|
| 264 | 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c2020. |
|---|
| 264 | 4|c©2020 |
|---|
| 300 | |a1 online resource (iv, 41 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Lignes directrices pour l'analyse de l'incidence du prix d'un médicament : lignes directrices pour l'analyse de l'incidence du prix d'un médicament sur les budgets des régimes d'assurance-médicaments. |
|---|
| 500 | |a"June 2020." |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references (pages 33-34). |
|---|
| 520 | |a"Budget impact analyses (BIAs) are used to predict and understand the potential financial impact of introducing a new pharmaceutical into a drug reimbursement system that has finite financial resources. While BIAs focus on the financial impact of the new drug, the value to the overall healthcare system is examined through other economic analyses, such as cost-effectiveness analyses (CEAs). In Canada, BIAs are used to make informed reimbursement decisions. These Guidelines provide a standardized approach and detailed recommendations for developing a BIA for submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) or to one of the participating federal/provincial/territorial (FPT) drug plans"--Introduction, page 1. |
|---|
| 650 | 0|aDrugs|xPrices|zCanada. |
|---|
| 650 | 0|aDrugs|xEconomic aspects|zCanada. |
|---|
| 650 | 0|aPharmaceutical services insurance|zCanada. |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
|---|
| 775 | 08|tLignes directrices pour l'analyse de l'incidence du prix d'un médicament : |w(CaOODSP)9.885895 |
|---|
| 795 | |tBudget impact analysis guidelines : |w9.689808 |
|---|
| 856 | 40|qPDF|s870 KB|uhttps://publications.gc.ca/collections/collection_2020/cepmb-pmprb/H82-49-2020-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/reports-studies/budget-impact-analysis-guidelines.html |
|---|